Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

Last Close
10.66
Jul 28 • 3:12 PM ET Dollar change-0.72 Percentage change(-6.29%)
Jul 27, 8:08 AMFreenome wins FDA approval for SimpleScreen CRC blood test, triggering $100 million milestone payment from Abbott
Index
-
Market Cap
109.99M
Enterprise Value
109.55M
Income
-0.76M
Sales
0.00M
Book/sh
7.64
Cash/sh
0.04
Dividend Est.
-
Dividend TTM
-
Dividend Ex-Date
-
Dividend Gr. 3/5Y
- -
Payout
0.00%
Employees
3
IPO
Jun 12, 2024
P/E
-
Forward P/E
-
PEG
-
P/S
-
P/B
1.40
P/C
249.97
P/FCF
-
EV/EBITDA
-
EV/Sales
-
Quick Ratio
0.20
Current Ratio
0.20
Debt/Eq
0.00
LT Debt/Eq
0.00
Option/Short
No / Yes
EPS (ttm)
-0.07
EPS next Y
-
EPS next Q
-
EPS this Y
-
EPS next Y
-
EPS next 5Y
-
EPS past 3/5Y
- -
Sales past 3/5Y
- -
EPS Y/Y TTM
-123.69%
Sales Y/Y TTM
-
EPS Q/Q
-116.28%
Sales Q/Q
-
Earnings
-
EPS/Sales Surpr.
- -
Insider Own
30.95%
Insider Trans
0.00%
Inst Own
-
Inst Trans
-
ROA
-0.86%
ROE
-0.92%
ROIC
-0.97%
Gross Margin
-
Oper. Margin
-
Profit Margin
-
SMA20
-7.41%
SMA50
-5.49%
SMA200
-9.01%
Trades
Shs Outstand
8.16M
Shs Float
5.02M
52W High
14.47 -26.30%
52W Low
9.95 7.18%
Volatility
16.35% 6.91%
ATR (14)
0.88
RSI (14)
40.36
Beta
0.32
Rel Volume
3.89
Avg Volume
191.65K
Volume
658,687
Perf Week
-18.03%
Perf Month
-2.43%
Perf Quarter
-5.04%
Perf Half Y
-24.90%
Perf YTD
-18.16%
Perf Year
0.70%
Perf 3Y
-
Perf 5Y
-
Perf 10Y
-
Recom
-
Target Price
-
Prev Close
11.38
Price
10.66
Change
-6.29%
Freenome, Inc. operates as a biotechnology company. It engages in the development of an early cancer detection platform. The company was founded in 2014 and is headquartered in New York, NY.
CEO & DirectorMr. Aaron Elliott Ph.D.
MHSMr. Cheng-Ho Lin M.D.
Chief Legal OfficerMr. Thomas F. Fitzpatrick J.D.
MSHRMs. Julie Tran M.B.A.
Senior Vice President of Regulatory & QualityMs. Sally Howard J.D.